People Willing to Trade Treatment Efficacy for Reduced Side Effects in Cancer Therapies
Nov 21, 2017
When choosing their preferred treatment, people with chronic lymphocytic leukemia place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a study published online in Blood Advances. The study also suggests that factoring out-of-pocket costs into this decision-making process may significantly influence a patient’s choice of treatment.
American Society of Hematology Announces Top Trainee Abstracts of 2017 ASH Annual Meeting
Nov 09, 2017
The American Society of Hematology (ASH) is pleased to recognize the following trainees with the highest-scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow at the 59th ASH Annual Meeting December 9-12 in Atlanta.
New Leadership Elected to American Society of Hematology
Nov 01, 2017
The American Society of Hematology, the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the election of three new members to its Executive Committee for terms beginning after the 2017 ASH Annual Meeting December 9-12 in Atlanta.